Clinical Trials

According to under the U.S. National Institutes of Health, the EU Clinical Trials Register, and the International Clinical Trials Registry Platform under World Health Organization (WHO) the following trials should be recruiting at this moment  (updated September 2021):

Assessment of the State of Health, Quality of Life and Expectations of Patients with HAE

– recruiting in France

Biomarker for HAE Disease

– recruiting in Armenia, Georgia, India, Peru, Poland, Romania, and Turkey

C1 Inhibitor Registry in the Treatment of HAE Attacks

– recruiting in Bulgaria, Croatia, Czech Republic, France, Germany, Hungary, Italy, North Macedonia, Norway, Poland, Slovakia, Slovenia, and Sweden


– recruiting in France

CSL312 (Garadacimab) in the Prevention of HAE Attacks

– recruiting in Canada, Germany, Hungary, Israel, Japan, the Netherlands, and the United States

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with HAE

– recruiting in Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, the Netherlands, Poland, Spain, and the United Kingdom

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants with HAE

– recruiting in Japan

Epidemiological Analysis for HAE Disease

– recruiting in Germany, Italy, Japan, Poland, Turkey, and the United Kingdom

Expanded Access Program with Lanadelumab for Japanese People With HAE

– recruiting in Japan

FIRAZYR General Drug Use-Results Survey (Japan)

– recruiting in Japan

Firazyr Patient Registry (Icatibant Outcome Survey – IOS)

– recruiting in Australia, Austria, Brazil, Czech Republic, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Spain, Sweden, and the United Kingdom

Global Registry to Gather Data on Natural History of Patients with HAE Type I and II

– recruiting in Italy

HAE Kininogen Assay

– recruiting in Germany

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of HAE Attacks

– recruiting in Australia, Canada, Germany, Israel, New Zealand, and the United States

Patient Registry to Evaluate the Real-world Safety of Ruconest

– recruiting in the United States

Quantifying the burden of disease and perceived health state in patients with HAE in Japan: Patient-Reported Outcomes study

– recruiting in Japan

Stopping androgen treatment in patients with HAE – characterization of reasons and protocols and development of advice for patients and physicians

– recruiting in France, Germany, and Hungary

Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants with HAE

– recruiting in Canada, Puerto Rico, and the United States

Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants with HAE

– recruiting in Austria, Germany, Israel, Switzerland, and the United Kingdom

The Role of the Coagulation Pathways in Recurrent Angioedema

– recruiting in France

Furthermore, these clinical trials are expected to be recruiting soon:

  • A clinical study to assess the safety of Lanadelumab to prevent episodes of severe swelling in children
  • A Study in Teenagers and Adults with HAE Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis
  • A Study of Lanadelumab in Teenagers and Adults with HAE in Argentina
  • A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With HAE
  • A study to investigate CSL312 in subjects with HAE Efficacy and Safety of GNR-038 vs Berinert in Patients With HAE
  • Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks – C1-INH HAE study
  • Long Term Safety Study of BCX7353 in HAE
  • Open-label Berotralstat Access to HAE Patients
  • Previously Enrolled in Berotralstat Studies
  • Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency

Read more about these and other clinical trials at

HAE related topics that might interest you

Global Access Program

Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program

Global Perspectives

Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community

HAEi Connect Member database

Free, secure online membership database and communications platform for HAEi’s member organizations

Regional Patient Advocates

Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized

Stay tuned – sign up for our newsletter


Click here to sign up

HAE Global Conference 2018

This 4th HAE conference was record breaking: A total of 736 patients and care givers participated from no less than 57 countries

HAEi hosted websites

Hosting of your national website or help for you to create a new website – naturally all in your native language